<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04183387</url>
  </required_header>
  <id_info>
    <org_study_id>SMV003</org_study_id>
    <nct_id>NCT04183387</nct_id>
  </id_info>
  <brief_title>Simvastatin in Uveitis</brief_title>
  <official_title>Open-label Randomized Study of Efficacy and Safety of Simvastatin in Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates anti-inflammatory effects and safety of simvastatin in non-infectious
      uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) have been shown to
      reduce local and systemic inflammation in animal models of various autoimmune disorders
      including uveitis. In this open-label, randomized study clinical efficacy and tolerability of
      simvastatin 40 mg/day for 8 weeks is evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of corticosteroid sparing control of ocular inflammation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incident cases of corticosteroid sparing control of ocular inflammation will be defined using following criteria:
≤0.5+ anterior chamber cells, ≤0.5+ vitreous haze, and no active retinal/choroidal lesions; and
≤10 mg of oral prednisone daily and ≤2 drops of prednisolone acetate 1% (or equivalent) a day;
The patient should fullfill both criteria to be classified as having corticosteroid sparing control of ocular inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Assessment of visual acuity using the Golovin-Sivtsev table</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior chamber cells</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>The grades for anterior chamber cells were 0 (&lt;1 cell), 0.5 (1-5 cells), 1 (6-15 cells), 2 (16-25 cells), 3 (26-50 cells), or 4 (&gt;50 cells)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior chamber flare</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>The grades are the following: 0 (none), 1+ (faint), 2+ (moderate (iris and lens details clear)), 3+ (marked (iris and lens details hazy)), 4+ (intense (fibrin or plastic aqueous)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitreous haze</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Nussenblatt scale:
0 (no flare), 0.5+ (trace), 1+ (clear optic disc and vessels, hazy nerve fiber layer), 2+ (hazy optic disc and vessels), 3+ (optic disc visible), 4+ (optic disc not visible)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>Measured using Maklakov tonometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tear IL-6</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Concentrations of IL-6 (pg/ml) in tear samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tear IL-8</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Concentrations of IL-8 (pg/ml) in tear samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tear IL-10</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Concentrations of IL-10 (pg/ml) in tear samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tear TNFα</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Concentrations of TNFα (pg/ml) in tear samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tear IFN-γ</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Concentrations of IFN-γ (pg/ml) in tear samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of corticosteroid sparing control of ocular inflammation</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incident cases of corticosteroid sparing control of ocular inflammation will be defined using following criteria:
≤0.5+ anterior chamber cells, ≤0.5+ vitreous haze, and no active retinal/choroidal lesions; and
≤10 mg of oral prednisone daily and ≤2 drops of prednisolone acetate 1% (or equivalent) a day;
The patient should fullfill both criteria to be classified as having corticosteroid sparing control of ocular inflammation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Simvastatin and standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg simvastatin per day for 2 months in addition to conventional treatment of uveitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>conventional treatment of uveitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 40mg</intervention_name>
    <arm_group_label>Simvastatin and standard treatment</arm_group_label>
    <other_name>simvastatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - diagnosis of active non-infectious uveitis

        Exclusion Criteria:

          -  serious liver or kidney disease

          -  increased transaminase levels of &gt;1.5 ULN

          -  planned or active pregnancy

          -  use of fibrates, nicotinic acid, cyclosporine A, antifungal drugs, macrolide
             antibiotics, verapamil, and grapefruit juice (&gt;1 L/day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Laboratory of Clinical Immunopharmacology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>November 28, 2019</last_update_submitted>
  <last_update_submitted_qc>November 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology</investigator_affiliation>
    <investigator_full_name>Ivan Shirinsky, MD, PhD</investigator_full_name>
    <investigator_title>Head of the Laboratory of Clinical Immunopharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

